# To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19.

> **NCT05351437** · PHASE1 · COMPLETED · sponsor: **Memo Therapeutics AG** · enrollment: 32 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **DRUG:** MTx-COVAB36
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05351437
- **Lead sponsor:** Memo Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-26
- **Primary completion:** 2022-09-04
- **Final completion:** 2022-11-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05351437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05351437, "To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05351437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*